Ono signs licence deal with NEX-I for cancer therapy

06 Mar 2024
www.pharmaceutical-technology.com
License out/inImmunotherapy
Ono signs licence deal with NEX-I for cancer therapy
Preview
Source: Pharmaceutical Technology
NEX-I focuses on overcoming the limitations of standard cancer treatments by targeting the underlying causes of refractory cancers. Credit: AshTproductions / Shutterstock.com.
Ono Pharmaceutical has signed an exclusive licence agreement for the development and marketing of NEX-I’s new cancer therapy, NXI-101.
An antibody drug candidate, NXI-101 targets the cancer immunotherapy-resistant factor ONCOKINE-1.
The target was discovered through NEX-I leveraging its target screening ONCOKINE platform.
It has potential efficacy against a range of cancer types, including those resistant to current cancer immunotherapies.
Ono will gain exclusive global rights to NXI-101 and its backup antibodies.
See Also:MorphoSys files patent for antibodies for treating inflammatory, autoimmune diseases, or cancer
Ono signs licence deal with NEX-I for cancer therapy
Preview
Source: Pharmaceutical Technology
Kura Oncology files patent for combination treatment for head and neck cancer
Ono signs licence deal with NEX-I for cancer therapy
Preview
Source: Pharmaceutical Technology
NEX-INEX-I is eligible to receive upfront payment, development and commercialisation milestone payments, apart from tiered royalty payments based on net product sales.
Ono Pharmaceutical discovery and research senior executive officer and executive director Toichi Takino stated: “We are pleased to collaborate with NEX-INEX-I having a proprietary ONCOKINE platform for development and commercialisation of NXI-101. We expect NXI-101 to be a new treatment option for cancer patients.
“Leveraging Ono’s experience and expertise in cancer immunotherapy, we will work on the development of the compound to add it to our development pipeline in oncology.”
A Korean biotechnology company established in 2021, NEX-I focuses on overcoming the limitations of standard cancer treatments by targeting the underlying causes of refractory cancers.
NEX-I CEO Kyoung Wan Yoon stated: “This collaboration aligns with NEX-I’s strategic focus on novel target discovery and the advancement of our flagship tumour microenvironment modulator, NXI-101.
“Through this landmark partnership, we underscore our commitment to identifying and developing novel and differentiated therapies that promise substantial benefits for patients.
“Our alliance with Ono represents a significant step forward for our ONCOKINE platform to assemble a diverse portfolio of clinical candidates across a broad range of mechanisms and therapeutic targets.”
The latest development comes after Ono entered a collaboration with Epsilon Molecular Engineering (EME) to advance drug discovery in the variable heavy domain of heavy chain antibodies.
The collaboration will utilise EME’s humanised VHH [the variable domain of heavy-chain IgG2 and IgG3] screening platform, known as The Month, to generate new antibodies for targets selected by Ono.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.